Galectins as potential pharmacological targets in renal injuries of diverse etiology

Eur J Pharmacol. 2020 Aug 15:881:173213. doi: 10.1016/j.ejphar.2020.173213. Epub 2020 May 22.

Abstract

Galectins are carbohydrate-binding proteins, and their importance in renal diseases of diverse etiology has been documented. Amongst different galectins, the role of galectin-3 in the pathophysiology of renal diseases has been well documented. There is an increase in galectin-3 in the circulation as well as on the kidneys in chronic kidney disease patients. The increase in galectin-3 is negatively correlated with a decrease in renal function and overall survival rate. The preclinical studies also correlate the increase in galectin-3 levels with renal dysfunction. Accordingly, scientists have exploited galectin-3 as a potential pharmacological target to improve renal functions in different preclinical models of renal injury. Apart from galectin-3, there have been few studies documenting the role of galectin-1, 8, and 9 in renal diseases. The role of galectin-1 is not clearly identified, and there have been conflicting reports regarding its role in renal diseases. Galectin-8 and 9 impart renoprotective effects as per clinical and preclinical studies, respectively. The present review discusses the role of different galectins in renal diseases of diverse etiology.

Keywords: Diabetes; Galectins; Glomerulus; Injury; Kidney; Nephropathy.

Publication types

  • Review

MeSH terms

  • Animals
  • Galectins / antagonists & inhibitors
  • Galectins / metabolism
  • Galectins / therapeutic use*
  • Humans
  • Kidney / drug effects*
  • Kidney / metabolism
  • Kidney / pathology
  • Kidney Diseases / drug therapy*
  • Kidney Diseases / etiology
  • Kidney Diseases / metabolism
  • Kidney Diseases / pathology
  • Renal Agents / therapeutic use*
  • Signal Transduction

Substances

  • Galectins
  • Renal Agents